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‘I’d rather not take Prozac’: 
stigma and commodifi cation 
in antidepressant consumer 
narratives
Regina Smardon1 
University of Virginia USA
a b s t r a c t  This article explores the idea that narrative is the primary vehicle 
through which antidepressant consumers negotiate their sense of identity and 
reality. Antidepressant consumers represent a unique consumer culture be-
cause of the stigma that society attaches to mental illness. Recent media 
attention, including direct to consumer (DTC) advertising, appears to decrease 
the stigma surrounding antidepressant use while at the same time commodi-
fying and branding them for mass consumption. Antidepressant consumers 
must negotiate the threat of stigma and the threat of commodifi cation through 
the process of constructing narratives. Exploring the narrative process of 
identity negotiation reveals how the interconnected cultural processes of 
stigma and commodifi cation are undergoing historical shifts. Among these 
shifts are the intensifi cation of branding and an expansion of consumer culture. 
Implications for health promotion and further research are discussed. 
k e y w o r d s  antidepressant branding; commodifi cation; consumer culture; 
narrative; stigma 
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[A]nd I like, I have to tell you that I like taking something that’s not Prozac or 
Zoloft; it’s just this thing that nobody knows about. Umm so… 
I didn’t attach it to anything in particular… it’s just enigmatic enough that 
I wouldn’t… you know like if somebody looked in my medicine cabinet they 
wouldn’t know. Not like anybody would look in my medicine cabinet.
(Celexa consumer)
Antidepressant consumers have a special relationship to cultural represen-
tations of antidepressants. Consumer cultures that form around pre-
scription drugs may help illuminate how lay cultures form in response to 
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commodifi cation. Vuckovic and Nichter (1997: 1297) argue that, ‘Through 
metonymic as well as metaphoric association individuals come to be defi ned 
by the medicines which they consume as well as the images associated with 
these commodities’. I would like to demystify this idea by exploring how 
people formulate antidepressant narratives within a cultural landscape of 
stigma and commodifi cation.
Despite the relative absence of work exploring the meaning of medicine
in consumer cultures there is a great deal to be gained from mining the rather 
large body of work devoted to studying illness narratives (Frank, 1995; 
Mattingly and Garro, 2000; Kleinman, 1988). There is also a great deal to be 
gained by revisiting classic sociological studies of drug use such as Howard 
Becker’s study of marijuana use (Becker, 1963) and Alfred Lindesmith’s 
study of opium use (Lindesmith, 1947). Despite their focus on elicit drugs, 
these studies highlight the sociality of the drug use experience. The meaning 
of medicine has been explored as part of an illness career (Conrad and 
Schneider, 1980; Goffman, 1959a; Karp, 1993). This work builds on Erving 
Goffman’s insights about the presentation of self in society (1959b) and 
the management of stigma (1963). Research on the meaning of noncompli-
ance has extended debate around the meaning of medication. Cohen et al. 
(2001: 445) point out that, ‘[N]on-compliance – irrational from a medical 
standpoint – may express, as various authors have proposed, deliberate 
strategies by patients to affi rm their autonomy, or to reject an attributed 
incapacity’.
Combining the study of illness narratives, the meaning of medicine and 
the concept of stigma management, provides the foundation for linking the 
micro-sociological process of consumer meaning making in face-to-face 
interactions with more macro-socio-cultural patterns of consumption and 
production. Sidney Mintz notes in his classic study of sugar production 
and consumption, ‘As uses change or are added on, as use both deepens and 
broadens, meanings also change’. (Mintz, 1985). Similarly, the relationship 
between the production and the consumption of antidepressants has 
changed over time as their uses have broadened.2 Commodifi cation makes 
the unique common. As commodities, antidepressants exemplify the empir-
ical complexity that pharmaceuticals offer the study of globalization pro-
cesses. In certain respects, pharmaceuticals are not common things and thus 
have much to offer a theory of the social life of things (Appadurai, 1986). 
They are not common in the sense that prescription medicine requires the 
judgment of an expert to provide an individualized diagnosis and treatment 
plan tailored to a patient’s specifi c needs.3 Antidepressants may also take 
on a singular meaning when they serve as a trigger for personal change and 
reinterpretation of self (Karp, 1996) or as a means of reconfi guring social 
relations of responsibility (Nichter and Vuckovic, 1994). Cohen et al. (2001) 
argue that these and other meanings of psychotropic medication are topics 
that deserve greater attention. Indeed, the sense that lay culture makes of 
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these medications may be very different from those intended by advertisers 
or health professionals.
The transformation of a prescription drug from strictly a tool of medical prac-
tice to a product that may be sought or declined on the basis not only of ‘lay 
knowledge’ but, more precisely, consumer product knowledge, could have 
profound implications given the ways in which such knowledge is obtained, 
perceived and applied (Cohen et al., 2001: 453).
Antidepressants are things-in-motion that warrant methodological focus 
because they can serve to illuminate their human and social context 
(Appadurai, 1986). Antidepressants are uniquely suited to the study of 
commodifi cation because of the rapid expansion of their use since the 1950s 
(Healy, 1997) and their status as the top-selling category of prescription 
drugs in the USA (NIHCM, 2002). Available estimates suggest that global 
sales of antidepressants and mood stabilizers were the third-ranked 
therapy class, up 10% in 2003, to $19.5 billion (IMS, 2004). Therefore, 
antidepressants are rapidly becoming a globalized commodity.
Collecting antidepressant narratives
The decision to take antidepressants is not an unthinking one in which 
people blindly follow their doctors’ orders, nor do people simply follow 
the advice that pharmaceutical companies deliver on prime time television. 
In his interview-based studies of the depression experience, David Karp 
found that people’s willingness to begin a drug treatment involves a host 
of complex considerations not the least of which is the ambiguity sur-
rounding the causes of depression (Karp, 1993, 1996, 2006). I set out to 
discover the meaning of antidepressants in people’s illness narratives, much 
the same way that Karp did for his latest book (Karp, 2006). In light of 
recent developments concerning direct to consumer (DTC) advertising,
it is instructive to note the similarities and differences in Karp’s fi rst 
interviews, collected between 1991 and 1993 and his later interviews, 
collected post-2001.
Although Karp’s analysis does not focus on commodifi cation or con-
sumer culture specifi cally, he reports extensively on the meaning of anti-
depressants, and his informants clearly possess brand awareness. My own 
interviews collected in 2000 echo this brand awareness.
Both Karp’s work and my own are based on retrospective narratives. 
Many of the people in Karp’s earlier study appear to have been diagnosed 
with depression before the introduction of Prozac in 1987. Karp’s post-2001 
interviews suggest a more critical orientation to medical authority than his 
work based on interviews collected in the early 1990s (Karp, 2006: 233). 
He complains that TV representations of antidepressants tend to leave the 
impression that they are infallible. On the other hand he also complains 
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that anti-psychiatry fi gures, such as Peter Breggin, strike him as ideologues 
(Karp, 2006).
Like Karp, I had an easier time identifying women for interviews than 
men, therefore I interviewed 10 women and 6 men.4 I advertised for people 
who are currently taking or have taken antidepressants, thus I was seeking 
antidepressant narratives not depression narratives. Like Karp, I developed 
a snowball sample through acquaintances and supplemented those inter-
views with volunteers who responded to my newspaper advertisement. 
My approach to interviews was inspired by the active interview model 
(Holstein and Gubrium, 1995), in which my informants were free to shape 
the direction of the conversation. I began each interview by simply asking: 
When was the fi rst time you ever heard about antidepressants? Whenever 
possible, I asked for clarifi cation about the meaning of medication.
‘I’d rather not take Prozac’
The antidepressant consumers I interviewed seemed to be very aware of 
brand names; this was particularly true of the young women I interviewed. 
These consumers seemed to be knowledgeable about different classes of 
antidepressants and they seemed to have a highly developed vocabulary 
for describing antidepressant mechanisms of action and linking brand 
names to these mechanisms. While Karp’s 1990’s interviewees seem to be 
parroting their doctor’s descriptions of antidepressants (see Karp, 1996: 
78–103), many of the people I interviewed referred to other sources of 
information; chief among these sources were fellow antidepressant con-
sumers who possess the authority of personal experience. Karp’s post-
2001 interviewees also seem to have a more critical edge than his previous 
sample, the interviewees advocating searching out information beyond 
a doctor’s advice (Karp, 2006: 232–6).
Although my sample is hardly representative, combined with Karp’s 
study it seems likely that antidepressant consumers were more likely to 
fi nd one another in the late 1990s than the late 1980s because a) There are 
more of them, and/or b) Society is becoming more open to antidepressant 
treatment. It seems likely that the introduction of direct to consumer 
(DTC) advertising of prescription drugs to the US market in 1997 has 
encouraged the formation of consumer cultures. None of my interviewees 
can be said to have ‘discovered’ their depression as a result of the direct to 
consumer advertising (DTC) that emerged after 1997, most were well aware 
of DTC advertising and some tended to resent it very much. In particular, 
some who suffered from serious and/or chronic mental illness worried 
that advertising served to belittle their plight rather than reduce social 
stigma.
To my knowledge there did not exist any television advertisements for 
antidepressants that discussed ‘suicidal ideations’ during the time period 
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that my narratives were collected.5 Instead, they tended to focus euphem-
istically on sadness, irritability, worrisome thoughts and loss of interest. 
In addition to misrepresenting mental illness, antidepressant advertising, 
for both professionals and the lay public, tends to overstate the effects of 
medicine (Goldman and Montagne, 1986; Montagne, 2001).6
In her book, No Logo (2000), Naomi Klein documents how particular 
brands (the swoosh, the shell and the arches) have been reframed by activ-
ists to represent corporate misdeeds. My interviews with antidepressant 
consumers suggest that Prozac had already fallen out of fashion by the 
year 2000. My conversation with a woman that I call Helena illustrates how 
stigma can adhere to a brand name:
author: What kind of antidepressant did they give you?
Helena: Um a serotonin reuptake inhibitor.
author: Prozac?
Helena: No, it was Celexa. Which is a European antidepressant and I had really 
good results. And I wasn’t too keen on taking... I’d rather not take 
Prozac. Just because of all the stuff attached to that. So…
author: Did you think that anything bad would happen if you took Prozac? 
Were you afraid of it?
Helena: No, I wasn’t afraid of it, I just, you know if there were another one 
that could be effective that didn’t have this mystique about it.
Helena’s desire for the newest brand name may suggest that antidepres-
sants are associated with better technology and advanced scientifi c research. 
However, Helena views all SSRIs as relatively interchangeable drugs that 
work through the same mechanism. Follow-up questions revealed that she 
does not necessarily believe that Celexa works better than Prozac. Her 
motivations can only be understood by taking the stigma associated with 
Prozac into account. Helena was probably the most open individual I 
interviewed with regards to revealing her illness identity and her choice to 
take antidepressants. However, like all the other antidepressant consumers 
I talked to, she still prefers the safety of those who understand and are 
sympathetic. During my interview with Helena in her offi ce, a co-worker 
entered the room to get a drink of water and she abruptly changed the 
subject. After he closed the door behind him, Helena leaned toward me to 
whisper:
Helena: He takes antidepressants.
author: Really?
Helena: It is very interesting how people … I was getting a prescription fi lled at 
the drug store and there were a lot of people there and there was this 
guy in front of me. And she said do you have any questions about taking 
Celexa and he said no. But I was like, hey he’s taking antidepressants, 
you know when you become aware of something it’s like …
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author: And you might not have known what Celexa was before you started 
taking it?
Helena: Right yeah right … and I like, I have to tell you that I like taking 
something that’s not Prozac or Zoloft; it’s just like this thing that 
nobody knows about. Um so …
author: What does the word make you think of?
Helena: I didn’t attach it to anything in particular … it’s just enigmatic enough 
that I wouldn’t … you know like if somebody looked in my medicine 
cabinet (author: Right.) they wouldn’t know. (author: mmm) Not like 
anyone would look in my medicine cabinet. (Helena laughs)
Prozac, it appears, has come to represent American excess and narcissism. 
If we listen carefully to Helena, we can hear her telling us that she wants to 
control information about her antidepressant use. George Ritzer argues 
that branding is used as a façade to hide ‘nothingness’. (Ritzer, 2004). All 
SSRIs, from a medical point of view, are more similar than they are different. 
Clinical trials do not suggest that SSRIs are really any more effective than 
tricyclic antidepressants (Montagne, 2001). Most research and marketing 
efforts surrounding antidepressants appears to focus on side effects and 
expanding indications for use to new disorders rather than pioneering new 
treatments.
‘I know tons of people taking antidepressants’
I would like to suggest that in the United States prior to 1997, and to a lesser 
extent today, becoming an antidepressant consumer was a process pregnant 
with stigma potential. However, as the threat of stigma recedes, a new threat 
emerges, the threat of commodifi cation. Those who have spent time in mental 
hospitals and found themselves in the emergency room for suicide attempts 
are symbolically victimized when they are mistaken for the antidepressant 
user who is depicted in the mass media as simply irritable and dissatisfi ed. 
This gap between representations of illness and healing and actual experi-
ence tends to dilute one’s self-narrative by robbing the individual of narrative 
resources. In a sense it creates an existential crisis by denying reality as 
some people know it. Indeed, Charmaz (1983) describes the dilution of self 
as being a great source of suffering associated with chronic illness. How 
can we reconcile what we know about the intense meaningfulness of stigma 
with the meaning gap generated by commodifi cation?
Due to the strong social stigma surrounding mental illness, even family 
members may keep their antidepressant consumption secret from one 
another until it seems likely that another person can benefi t from this 
information. Although most people claimed that they felt as though they 
‘know tons of people on antidepressants,’ many found it diffi cult to think of 
more than one person that shared this information with them prior to their 
own use, especially before 1997. It appears that having access to a social 
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network, especially a community of antidepressant consumers, decreases the 
stigma associated with antidepressants and that taking the drugs increases 
one’s access to this network. Research on antidepressant consumption has 
not explored the role of the antidepressant consumer network in shaping 
experiences of stigma. While most of the people I interviewed did not be-
lieve that taking antidepressants was shameful, they were acutely aware 
that others might think so.
The theme of stigma in this collection of antidepressant narratives should 
be viewed as historical. The past several years have been a changeable time 
period for the cultural meaning of antidepressants. Some would argue that it 
seems as though it is only a matter of time before antidepressants are viewed 
as being completely commonplace in society. Perhaps in some communities 
they already are. I am not conceptualizing stigma and commodifi cation as 
a zero sum game: less stigma does not necessarily equal more commodifi -
cation and vice versa. There is a more fundamental narrative process that 
drives the dynamics of stigma and commodifi cation.
Sometimes, people look to the media for narrative ingredients but the 
representations are too thin to provide a satisfying story. Mary was very 
limited in her social network and also in the media sources at her disposal. 
She describes her attempt to make sense of a representation of depression 
and antidepressant treatment from television. When I asked her about her 
social network, she spontaneously mentioned a television show that coin-
cidentally aired while she was in the midst of deliberating about treatment 
options.
Author: Did you discuss your decision about taking the antidepressants with 
anybody besides your doctor?
Mary: Um well, I think I talked about it with Annie, with um my boyfriend, 
um I think I just told my mom. I don’t think she really understood. I 
was just like, ‘well, this is what they’re doing’. I just sort of announced 
it. Um, … well there was an Ally McBeal show and she was prescribed 
Prozac and the character that played the psychiatrist said happiness 
does not come in church, a man, love, church any of these things, she 
listed off a lot of different things, it comes in a pill. It was really sort of 
depressing. And in the end Ally fl ushed away the Prozac. And I was 
thinking oh boy tomorrow I’m supposed to be starting my Klonopin, 
that’s when I started Klonopin which is an anti-anxiety …
Author: Mmhmm.
Mary: And it worked to help me fall asleep, temporarily …
Author: What did you think about the Ally McBeal show at the time?
Mary: I thought Ally needs it more than me (laughs); the character Ally needs 
it more than me. I think she should try it, I think also that the show 
generally addressed everything and like you know she’s not gonna take 
Prozac, sounds like a great thing, but I think if they were to do it a more 
believable thing I think she should have tried it.
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Mary did try taking antidepressants as she suggested Ally should. She 
discontinued her use after ten days without consulting her doctor. She did 
not consult with any friends or family because, as she points out in the inter-
view, they do not understand. She attempts to construct a narrative that 
frames her experiment with antidepressants as a good effort. She seems 
disturbed by media representations that suggest that this effort is in vain.
Mary still has problems with depression and sleep, and a treatment seems to 
constantly elude her. Mary’s story would have required narrative elements 
that her doctor could not supply in order to continue her medicine use. 
For one thing she was not convinced that waiting more than ten days 
was necessary to evaluate the results of the drug. She was not convinced 
because the narrative ingredients provided by her doctor did not allow her 
to construct a satisfying story to explain her experience. Perhaps a more 
detailed media representation might have enabled Mary to incorporate a 
period of suffering that included side effects into the beginning of her drug 
trial. Perhaps a narrative of a friend who ultimately recovered through her 
use of antidepressants would have provided crucial narrative elements.
When I asked Heather who she talked with about her treatment deci-
sions she described her family as a depression support network and a 
clearinghouse of information about depression. She has eight siblings; fi ve 
have taken antidepressants. She does not seek out people to talk to about 
her treatment decisions because she relies on her family and the media 
sources that they supply her.
We’ve all read like we always read all the like the novels or the new books that 
come out about depression or like there’s a lot of memoirs out now about women 
who’ve had depression and um, you know, like that … that one … there’s that 
one woman … um … so its funny because we’ve all read all of those, like my 
mom just sent me this book called checked or just checking? Have you heard of 
that one? It’s good, it’s written, its kind of like a memoir. It’s breezily written in 
little passages by this woman who clearly had OCD and how it sort of ruins her 
marriage, but it’s really funny. She tells it in this funny little … and then there’s 
that one woman who wrote two memoirs, one was about growing up Catholic 
and the other one is about like depression, I don’t know her name. Maybe that’s 
why I don’t have a bigger circle or peers because I was always reading these 
books too so I was always like—and that was the other side of my depression 
network were these books and articles. (Heather)
The memoirs supply crucial narrative ingredients that clinical encounters 
often fail to include. For example, there is a detailed discussion of a failed 
relationship, a ruined marriage in one of the memoirs described by Heather. 
These memoirs also help Heather fi nd humor in her own misfortune, a 
feature that helps her to heal. Heather is a person who has adjusted or 
changed her medication several times over the past several years. She has 
even volunteered for a drug trial study. She feels satisfi ed with her own 
antidepressant narrative and she does not seek out new people to compare 
her story with. In fact she described an incident when a co-worker sought 
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her out for details about her experience and how she did not have any 
interest in this information exchange saying, ‘I thought that what she kind 
of wanted was somebody you know to go over all the symptoms and of 
the things and I’m just, I don’t want to do that’. If my premise is correct, the 
woman who sought out Heather does not have access to a support network 
of people with fi rst-hand knowledge of depression or antidepressants. What 
this woman is after is not simply clinical knowledge but a narrative form 
that she can employ that makes sense of her experience.
Why does Mary discontinue her antidepressant use after only ten days 
while Heather is willing to pursue different brands and dosages and even 
cocktails to fi nd a therapy that works for her? Part of the reason may be that 
Heather has access to fi rst-hand antidepressant narratives from her family. 
Mary conversely does not have access to nuanced antidepressant narratives. 
Her attempt to squeeze meaning out of the thin narrative supplied by a tele-
vision program highlights her need for cultural resources. Ultimately, she 
believes that her supporters ‘don’t understand’.
Commodifi cation and stigma surrounding antidepressants are related 
but distinct phenomena. Although commodifi cation appears to reduce 
stigma, there are hypothetically other ways, perhaps better ways, that 
pubic awareness can be created about this treatment option. The cultural 
circulation of antidepressants in the media has raised public awareness of 
treatment options while at the same time failing to provide rich and diverse 
illness narratives. Hypothetically, this need not be the case, the cultural cir-
culation of antidepressants could lead to the production of rich and diverse 
antidepressant narratives shared within social networks and also circulated 
in the media.
Negotiating the spoiled and commodifi ed self through 
narrative
As a bricoleur, the self-constructor is involved in something like an interpretive 
salvage operation, crafting selves from a vast array of available resources, making 
do with what he or she has to work with in the circumstances at hand, all the 
while constrained, but not completely controlled by the working conditions of 
the moment (Holstein and Gubrium, 2000: 153).
Students of consumer culture(s) have questioned the image of the consumer 
as a ‘dupe’ or a ‘hero’ (Slater, 1997). Contemporary debates surrounding 
consumer culture have begun to question the image of the consumer as 
a ‘postmodern identity seeker’ who chooses freely between lifestyles and 
identities (Featherstone, 1991) and instead settled on the more laborious 
metaphor of the craftsman (Campbell, 2005). This metaphor seems a fi tting 
homage to the legacy of Claude Levi Strauss ([1949]1966) who encouraged 
us to view the cultural actor as a bricoleur, a handyman. I propose that we 
view the consumer as a storyteller who creates an identity narrative using 
existing cultural elements and synthesizes them into a new expression. 
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This storytelling is a form of cultural labor.7 The bricoleur consumer is 
limited by the cultural meanings and forms at his/her disposal. Stigma and 
commodifi cation are forces that limit the choices available to consumers 
and perhaps at times trigger a ‘decommodifying reaction’ (Campbell, 2005; 
Kopytoff, 1986; Miller, 1987).
Consumers must contend with a limited selection of narrative forms and 
a limited vocabulary of cultural elements available to tell their stories. As 
Holstein and Gubrium (2000) note, the storyteller is also limited by the 
working conditions of the moment. They must incorporate an explanation 
of past, present and future social occasions and relationships. The com-
plexity of this task explains why a consumer may be willing to accept a stig-
matized label into their identity narrative and why others may encourage 
them to do so. The social stigma and social uses of the depression label must 
be considered when analyzing the forms of antidepressant narratives. The 
infl uence of social interactions and social relationships on one’s orientation 
towards antidepressants cannot be separated from the subtle effects of 
labeling depression as emotional deviance. Depression is a long-term mood 
that is generally regarded as deviant in American society. However, the 
social construction of depression requires a script for linking instances of 
emotional deviance together under a single umbrella label. The labeling of 
deviant moods can be very subtle and relies on innuendo, manner, un-stated 
implications and especially emotion (Scheff, [1666]1999; Thoits, 1985).8 
Edwin Lemert points out that it is ‘behavior which puts a strain on social 
relationships that leads to status changes’ (Lemert, 1962). He encourages 
us to consider that the paranoid individual may in fact rightly suspect that 
others are avoiding them or treating them differently. Those that I inter-
viewed experienced a range of labeling effects from overt to covert. In some 
cases a person was so sensitive to the idea that their behavior might be 
labeled as mentally ill that they anticipated the judgments of others.
Helena initially rejected the label of depression when her therapist 
suggests it because she had not undergone the crucial step of self-labeling 
her own feelings as deviant. The second time that her therapist suggested 
the label of depression Helena accepted it as confi rmation of her own 
suspicion that something is wrong.
Well I guess I questioned it fi rst of all. And second of all I was seconded by my 
therapist. She said yeah I think you’ve had a low grade depression for a while. 
And um and actually now that I remember, she had said that two years ago. 
Maybe a year prior to my going on the antidepressant. And I went to a psy-
chiatrist and the psychiatrist said no you’re not depressed. And I was like ha ha 
ha I’m not depressed, you’re wrong and I’m just you know … So I knew that it 
wasn’t normal when I was questioning it and then through talking about it to her. 
And the resilience that I used to have wasn’t there. (Helena)
Helena was not willing to label what her therapist called a ‘low grade 
depression’ anything other than ‘feeling blue’ until a signifi cant period of 
time had passed. After a year she felt that something was defi nitely wrong 
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because she had not ‘bounced back’ as she had expected. Helena imagined 
herself as a person who always ‘bounces back’, and giving up that identity 
was diffi cult. Thomas also experienced the label of depression as contrary 
to his sense of self. He felt that medicalizing his suffering made it meaning-
less and shallow.
I didn’t like the word depression. I thought it was terrible. In my hyperliterary 
state I thought it was an awful word, you know, I preferred melancholy you 
know. Because that had more of a literary history too it, so I thought OK. But 
I was very resistant to the idea that what I had was clinical depression. So to me 
what I had was hypersensitivity to the side of life that ... the dark side, the void, 
that life was just a painful experience. That’s what I had, I didn’t have depression. 
I didn’t really admit that I had depression for a few years. Even when I was in the 
hospital I wasn’t willing to admit that I was just one of many many people that 
suffered from this. (Thomas)
For Thomas and for Helena, accepting the label of clinical depression 
meant shifting their frameworks for experiencing a sense of self. They 
both initially resisted this shift but gradually changed their minds about 
both the label of clinical depression and the effi cacy of antidepressants. 
Why did they shift their narratives? Perhaps because over time their 
narrative became less and less satisfying and explained less and less of 
their experiences. Perhaps the threat of commodifi cation outweighed the 
stigma of a spoiled identity. Thomas does not want to be just one of many 
homogenized people to suffer in the exact same way. He wanted to suffer 
in a unique and singularly meaningful way. He did not want to let go of 
his view of himself as sensitive and literary just as Helena did not want 
to give up her narrative of resiliency and the idea that she would always 
‘bounce back’. They found that an alternative narrative fi t their experience 
more closely. Helena seems to be fearful of stigma, suggesting that taking 
antidepressants would make her weak. Thomas seems to be suggesting 
that antidepressants are commodifi ying; they will make him just like all the 
other depressed people. It is not insignifi cant that Thomas has a history 
as an inpatient and has suffered from severe depression while Helena was 
an outpatient whose depression was self-described as ‘mild’. Yet, the pro-
cess of negotiating stigma and commodifi cation does appear to follow a 
similar structure in which an alternative narrative is initially resisted until 
it becomes clear that the gap between narrative and evidence is growing 
and a new narrative offers decisive advantages.
Discussion: What can we learn from antidepressant narratives?
The view of prescribed medication as a rapidly changing meaningful 
object has been virtually absent from the study of medication consumption 
(Cohen et al., 2001), and medicine socialization itself is a research topic 
little explored by either social science or pharmacology (Vuckovic and 
Nichter, 1997). To be sure, studies of pharmaceutical practice have not 
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to date suffi ciently explored the construction of mass media consumer 
cultures (Cohen et al., 2001; Van der Geerst et al., 1996). Social scientists 
have pointed to the need to link micro-level investigations of illness identity 
and explanatory models with macro-level investigation of pharmaceutical 
use (Nichter and Vuckovic, 1994). Focusing on consumer culture highlights 
the fact that consumers have a special relationship with one another that 
is distinct from their relations with social institutions, such as the media or 
medical authorities. These relations constitute a response to commodifying 
forces and this response reconfi gures the dynamics of stigma.
Widespread awareness of name brand prescription medications presents 
a particularly interesting case of what Kopytoff calls singularization and 
commodifi cation (Kopytoff, 1986). Commodifi cation of medicine requires 
homogenization of the disease or disorder associated. The commodifi cation 
of mental illness involves the blurring of boundaries between discomforts 
of daily living and psychiatric symptomotology, suggesting that both can 
be remedied through mass-marketed products (Rubin, 2004). Commodifi -
cation of an illness can threaten a consumer’s singular experience, suggesting 
that their pain and suffering is common and meaningless. Somewhat para-
doxically, general awareness of antidepressants as a viable treatment option 
in society appears to loosen the hold of social stigma surrounding their use.
Public awareness of antidepressants could be interpreted as an opening 
for consumers to defi ne their own healing process and wrest control away 
from the domain of physicians.9 However, doctors and consumers are not 
the only players defi ning the meaning of antidepressants in society. Medical 
sociologists are beginning to acknowledge that the medicalization of social
problems is currently being driven by biotechnology, consumers, and 
managed care in the United States (Conrad, 2005) and abroad (Lakoff, 
2004).10 Recent scholarship has begun to explore antidepressant marketing 
strategies that pharmaceutical companies use in the USA (Healy, 2006) and 
abroad (Applbaum 2006; Lakoff, 2006). This literature does not consider 
the dynamics of consumer culture in this process. Indeed, what is missing 
from this discussion is an understanding of how the intertwined cultural 
processes of stigma and commodifi cation unfold as narratives within the 
context of consumer cultures.
Advertisers are motivated to expand the potential market for medicine 
to the mildly ill. The mildly mentally ill represent a large potential market 
because they are not yet diagnosed and have not yet acquired a brand pre-
ference. It is not in the advertiser’s interest to represent the full range of 
mental illness through the media. What exactly are the motivations that 
drive the antidepressant consumer and where do they look for cultural 
information about their medicine? A rational actor model would suggest 
that consumers are motivated to reduce costs, pursuing for example generic 
SSRIs (Selective Serotonin Reuptake Inhibitors) over expensive new 
brands. Yet, we know that such utilitarian concerns can only partially 
explain the complexity of antidepressant use and its current expansion. 
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Among the important social processes interceding the path to the physician 
(Zola, 1973) is access to other antidepressant consumers.
Cultural representations do not predict the experience of stigma; they 
simply mediate it. In contrast to an approach that tries to connect cultural 
representations of illness to the experience of stigma (Link et al.,1989; Link 
and Phelan, 1999; Phelan and Link, 1999), some medical sociologists and 
anthropologists have emphasized the healing role of narrative. Although 
my analysis reaffi rms the power of stigma in shaping the experience of mental 
illness, it also suggests that narrative process further shapes the experience 
of stigma. Recall that the stage a person occupies in forming their narrative 
determines their receptiveness to accepting a label, even in some cases of 
involuntary hospitalization. Phil Brown (1995) has described the therapeutic 
value of diagnosis for many patients and Arthur Frank (1995) has written 
about the therapeutic value of rhetorical devices that allow stories to be 
told through a ‘wounded body’. A narrative is provided, or created, for pre-
viously unexplained events and experiences rendering the world and one’s 
place within it more predictable. This approach suggests asking what con-
ditions cause an individual to interpret the stigma of mental illness as out-
weighing the existential pain of lacking a sense of identity. Stigma spoils an 
identity but it does not erase one’s sense of identity altogether. When does 
a commodifi ed identity become a larger crisis than a spoiled one?
Ethnomethodologists have long noted the attachment that individuals 
have to a particular version of reality, and their violent reactions to those who 
breach that reality (Garfi nkel, 1967) and Erving Goffman (1959b, 1963) 
often observed that people present a line about themselves to the public 
world. The need to present a coherent narrative about the self and about the 
world in general may partially explain the reactions or coping orientations 
that individuals employ in response to the threat of stigma. Secrecy may be a 
strategy for managing discrediting knowledge about one’s mental illness or 
it may be a strategy to ward off the threat of commodifi cation; maintaining 
a particular narrative about one’s place in the world. Peggy Thoits’ work on 
self-labeling suggests that people can be sensitive to maintaining their self-
image as well as the one they put forth for others to inspect (Thoits, 1985). 
Not only are people managing discrediting knowledge; they are also pro-
tecting their identity narrative from criticism and chaos. They are protecting 
their own image of themselves, a higher-order priority than impression 
management.
Conclusion: Turning stigma and commodifi cation into healing
The analysis I have presented here suggests that avoiding stereotypes about 
the mentally ill will likely decrease stigma but it is not likely to prevent 
the process of commodifi cation. The fi ner details of the illness and healing 
experience must be validated and circulated to combat this process. Those 
interested in health promotion are beginning to realize that pharmaceutical 
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companies cannot be relied upon to educate the public about mental illness 
(Hollon, 2005). The media, signifi cant others and health professionals 
provide meanings about antidepressant use that serve as tools for making 
stories. The antidepressant user is a storytelling craftsperson who is limited 
by available cultural resources including narrative forms. To the extent that 
the media limits representations, this serves to diminish the storyteller’s 
options. In the case of depression, reducing the threat of stigma and the 
threat of commodifi cation is a very real part of the healing process.11 When 
people share their various antidepressant narratives among themselves, 
this trend seems to broaden and deepen representations.12 Arthur Frank 
(2006) claims that the important ethical task of narrative analysis is to put 
more stories into circulation. This insight deserves more systematic research 
so that it can be applied effectively to health promotion policy.
Research on DTC advertising tends to focus on doctor surveys. The 
primary research questions driving these studies: 
1. Does DTC advertising infl uence the doctor–patient relationship? This is 
usually operationalized as doctor prescribing practices. 
2. Are consumers more knowledgeable as a result of DTC advertising? 
3. Does DTC advertising contribute to the rising cost of health care? 
Available research generally suggests that the answers to these questions 
are yes, yes and yes, with some minor qualifi cations. Nobody is asking how 
DTC advertising contributes to a consumer’s efforts at creating an illness 
narrative. A true understanding of DTC advertising must include an analysis 
of consumer cultures.
It is possible to argue for both positive and negative outcomes asso-
ciated with the global commodifi cation of antidepressants. On the one 
hand, antidepressants can save lives when the market is expanded. When 
the fi rst SSRIs were introduced in Japan in 1999, the suicide rates dropped 
dramatically (Landers, 2002). On the other hand, branding of pharmaceu-
ticals and associated DTC advertising seems to be one of the major factors 
fueling the spiraling cost of healthcare in the US ultimately leaving many 
Americans unable to afford health insurance.13 Public awareness of 
psychiatric disorders and pharmaceutical treatment has burgeoned and 
the stigma associated has certainly decreased, allowing for the formation 
of communities and networks of people who share their antidepressant 
narratives. These antidepressant consumer cultures contribute to societal 
openness about psychiatric treatment. Tragically, the limited images of 
mental illness, healing and medicine that are circulated in the media tend to 
misrepresent the experiences of the mentally ill and distort the effectiveness 
of antidepressants.
This study is not nearly large enough to draw conclusions about the role 
of gender in the formation of antidepressant consumer culture, although it 
seems likely that this is an important feature deserving future study. The 
analysis I have presented must be treated as the best evidence available 
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on an under-researched topic. Our understanding of how antidepressant 
consumer cultures evolve is necessarily limited because the opportunity 
for antidepressant consumers to meet outside of the infl uence of medical 
authority has only become possible as stigma recedes. Note that even inter-
net chat groups and support groups for antidepressant consumers have 
tended to be sponsored by pharmaceutical companies and refereed by 
medical professionals. The characteristics that distinguish antidepressant 
consumer cultures from one another will be of particular interest to future 
research, and diverse research methodologies will be necessary to capture 
their emergence.
Certainly the infl uence that consumer culture, both inside and outside 
the USA, has on the pharmaceutical industry is a topic that deserves further 
attention. As antidepressants become more commonplace in not only 
Europe and Japan (Wehfritz and Itoi, 2001) but also in other places on 
the globe, we can begin to observe how media representations become 
incorporated locally into antidepressant narratives by consumers. Perhaps 
the most obvious place to begin this work is New Zealand, where DTC 
advertising has been legal since 1981. How do New Zealander antidepres-
sant consumer narratives compare with those in the United States?
Future research on antidepressant consumption could also explore the 
notion of ‘risk’ in response to the recurrent media scandals and lawsuits 
that claim particular brand-name antidepressants can actually cause sui-
cide and/or suicidal ideations in particular populations of patients (Elliot 
Chambers, 2004; Healy, 2004). Consuming antidepressant brands in this 
case is a form of consuming risk (Tulloch and Lupton, 2002) and can be 
compared to the dynamics of risk surrounding other products recalled or 
questioned by the FDA. Although the spectre of risk was present in the 
antidepressant narratives I collected, the idea that the medicine could 
actually cause suicide was not a major theme. Instead, consumers tended 
to ruminate about unknown long-term side effects and unpleasant, but 
certainly not lethal, short-term side effects. How do consumers who have 
worked hard to build their antidepressant narratives around the threat 
of stigma and commodifi cation reconcile this paradoxical risk? What 
role do consumers play in generating these media scandals?
Antidepressant consumers are a community interested in minimizing 
stigma and commodifi cation and maximizing healing through narrative. 
Future research on pharmaceutical consumption ought to take seriously 
how antidepressant consumers incorporate media representations to tell 
their antidepressant narratives; specifi cally, how they use media signals 
to identify what Erving Goffman (1963) called ‘the wise,’ in this case lay-
persons who are sympathetic to and/or knowledgeable about antidepressant 
use. This type of research will begin to suggest a culturally sophisticated 
understanding of the connections between consumer culture and commodi-
fi cation of antidepressants.
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Notes
 1. An early version of this article was presented at a round table titled: Cultural 
Representations of Illness and Medicine at the 2003 Eastern Sociological 
Meetings in Philadelphia. Thoughtful feedback to early drafts of this article 
were provided by Chloe Silverman, Charles Bosk, Diana Crane, Randall 
Collins, Danielle Kane, Laura Carpenter, Vida Bajc and Peter Buonaccorsi.
 2. Judith Swazey’s study of the discovery and use of Chlorpromazine (Swazey, 
1974) is a social history of the production of a pharmaceutical commodity. 
This book is useful for examining the relationship between the uses of early 
psychotropic medications and the institutional evolution of mental health care.
 3. Obviously, commodifi cation is a matter of degree. Evidenced-based medicine 
conceptualizes medical treatment as a standardized product, and by extension 
the patient becomes a consumer. Clearly, the growth of scientifi c management 
and managed care has advanced the commodifi cation of medical care. As Kirk 
and Kutchins (1992) point out, the DSM itself tends to commodify illness. I 
am focusing for the moment on the commodifi cation of prescribed medication 
itself, which I am treating as analytically distinct for the purpose of this study.
 4. Antidepressant consumers are in fact largely women. This is because two out 
of three adults diagnosed with clinical depression are women (Maier et al., 
1999; Nolen-Hoeksema, 1990). See Blum and Stracuzzi (2004) for an analysis 
of the gendered representations of Prozac in large-circulation periodicals. See 
Lovdahl et al. (1999) for a gender analysis and comparison of Scandinavian 
and American advertising for antidepressants to physicians. See also Nikelly 
(1995) for a discussion of gender, advertising and the medicalization of 
depression.
 5. It is interesting to note that mention of suicidal thoughts as a symptom of 
depression was to my knowledge not included in antidepressant television 
advertisements until after a series of media scandals involving research 
and law suits suggesting that antidepressants cause suicidal ideations. At 
this juncture it was in the best interest of the pharmaceutical companies to 
establish that suicidal thoughts are a feature of the disorder rather than the 
medicine.
 6. This is particularly true in light of Kirsch et al.’s (2002) fi ndings regarding 
placebo effects in antidepressant drug trials. Somewhat paradoxically, those 
who suffer from depression are often depicted as tragic unsung heros who 
must suffer chonically and silently without the aid of medication. Thank you 
to an anonymous reviewer for pointing out this nuance. My main argument 
here is that the diversity of suffering is depicted narrowly and strategically to 
target a particular market.
 7. Current references to the cultural actor as a bricoleur can be found in 
Holstein and Gubrium (2000), Urban (2001) and also are discussed at length 
in Erickson (2004). All of these references attempt to modify Levi-Straus’ 
structuralism and place the bricoleur in a more emergent social context.
 8. See David Karp’s The Burden of Sympathy (2001) for an account of how 
signifi cant others deal with mental illness.
 9. Paul Starr argues in The Social Transformation of American Medicine 
(1982) that the American Medical Association was largely responsible for 
manipulating the government through media muckrakers to establish the 
category of medicines that we now call ‘prescription drugs’. This series of 
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events, according to Starr, increased the professional power of physicians 
and played a role in creating the expensive medical system that now exists. 
Thus began a complex interdependency between pharmaceutical companies 
that relied on the authority of physicians to sell their products and physicians 
that rely on the pharmaceutical industry to supply the technology that 
legitimates their work. See Rubin (2004) for an analysis of the marginalization 
of physicians in psychotropic drug advertising beginning in the 1970s and a 
discussion of the connection between deinstitutionalization of the mentally ill 
and the institutionalization of psychotropic drug advertising.
10. To be fair, Renee Fox argued in 1977 that medicalization and 
demedicalization are diffuse cultural phenomenon that are not entirely driven 
by medical institutions and professions. Consumers are undoubtedly among 
the forces in society that she imagined driving the process of medicalization 
(Fox, 1977).
11. It is not insignifi cant that many health professionals consider loss of interest in 
previous activities and a slowing down of cognitive processing to be symptoms 
of depression.
12. Consider the wildly popular TV show, The Sopranos. This program includes 
a realistic portrayal of a patient’s relationship with his psychiatrist. If my 
hunch is correct, this program’s popularity in the early twenty-fi rst century 
can be explained, in part, by the cultural void that it fi lls. Tony Soprano’s 
antidepressant narrative includes a complex work and family life and a 
complex relationship with Prozac.
13. The Centers for Medicare and Medicaid Services have projected that between 
2001 and 2011 prescription drug spending will nearly triple (NIHCM, 2002).
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